Multiple sclerosis (MS) is a disease induced by demyelination in the central nervous system, and the remission period of MS is crucial for remyelination. In addition, abnormal levels of thyroid hormone (TH) have been identified in MS. However, in the clinic, insufficient attention has been paid to the role of TH in the remission period. Indeed, TH not only functions in the development of the brain but also affects myelination. Therefore, it is necessary to observe the effect of TH on remyelination during this period. A model of demyelination induced by cuprizone (CPZ) was used to observe the function of TH in remyelination during the remission period of MS. Through weighing and behavioral tests, we found that TH improved the physical symptoms of mice impaired by CPZ. Supplementation of TH led to the repair of myelin as detected by immunohistochemistry and western blot. In addition, a sufficient TH supply resulted in an increase in myelinated axons without affecting myelin thickness and g ratio in the corpus callosum, as detected by electron microscopy. Double immunostaining with myelin basic protein and neurofilament 200 (NF200) showed that the CPZ-induced impairment of axons was alleviated by TH. Conversely, insufficient TH induced by 6-propyl-2-thiouracil resulted in the enlargement of mitochondria. Furthermore, we found that an adequate supply of TH promoted the proliferation and differentiation of oligodendrocyte lineage cells by immunofluorescence, which was beneficial to remyelination. Further, we found that TH reduced the number of astrocytes without affecting microglia. Conclusively, it was shown that TH alleviated demyelination induced by CPZ by promoting the development of oligodendrocyte lineage cells and remyelination. The critical time for remyelination is the remission period of MS. TH plays a significant role in alleviating demyelination during the remission period in the clinical treatment of MS.
TrappBDPetersonJRansohoffRMRudickRMorkSBoL. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338: 278–85.
2.
WaxmanSG. Demyelinating diseases—new pathological insights, new therapeutic targets. N Engl J Med1998; 338: 323–5.
3.
ScoldingNFranklinR. Axon loss in multiple sclerosis. Lancet1998; 352: 340–1.
4.
WingerchukDMWeinshenkerBG. Multiple sclerosis: epidemiology, genetics, classification, natural history, and clinical outcome measures. Neuroimaging Clin N Am2000; 10: 611–24, vii.
5.
KisterIChamotESalterACutterGBaconTKalinaJHerbertJ. Natural history of MS symptoms: perceived disease impact across disease span in nine neurologic domains among enrollees in North American Research Committee on Multiple Sclerosis (NARCOMS) Registry. Neurology2012; 78: 19–27.
6.
VukusicSConfavreuxC. Natural history of multiple sclerosis. Presse Med2010; 39: 359–62.
7.
KantarciOHWeinshenkerBG. Natural history of multiple sclerosis. Neurol Clin2005; 23: 17–38.
8.
TremlettHZhaoYDevonshireV. Natural history of secondary-progressive multiple sclerosis. Multiple Sclerosis2008; 14: 314–24.
9.
KochMKingwellERieckmannPTremlettH. The natural history of primary progressive multiple sclerosis. Neurology2009; 73: 1996–2002.
10.
CrawfordDKMangiardiMXiaXLópez-ValdésHETiwari WoodruffSK. Functional recovery of callosal axons following demyelination: a critical window. Neuroscience2009; 164: 1407–21.
11.
LassmannHBruckWLucchinettiCF. The immunopathology of multiple sclerosis: an overview. Brain Pathol2007; 17: 210–8.
12.
ChangATourtellotteWWRudickRTrappBD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med2002; 346: 165–73.
13.
FrischerJMBramowSDal-BiancoALucchinettiCFRauschkaHSchmidbauerMLaursenHSorensenPSLassmannH. The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain2009; 132: 1175–89.
14.
MitewSHayCMPeckhamHXiaoJKoenningMEmeryB. Mechanisms regulating the development of oligodendrocytes and central nervous system myelin. Neuroscience2014; 276: 29–47.
15.
JiangYYangYZhangBPengFBaoJHuX. Cerebrospinal fluid levels of iodothyronines and nerve growth factor in patients with multiple sclerosis and neuromyelitis optica. Neuro Endocrinol Lett2009; 30: 85–90.
16.
DurandBRaffM. A cell-intrinsic timer that operates during oligodendrocyte development. Bioessays2000; 22: 64–71.
17.
TokumotoYMTangDGRaffMC. Two molecularly distinct intracellular pathways to oligodendrocyte differentiation: role of a p53 family protein. EMBO J2001; 20: 5261–8.
18.
BillonNTerrinoniAJolicoeurCMcCarthyARichardsonWDMelinoGRaffM. Roles for p53 and p73 during oligodendrocyte development. Development2004; 131: 1211–20.
19.
RogisterBBen-HurTDubois-DalcqM. From neural stem cells to myelinating oligodendrocytes. Mol Cell Neurosci1999; 14: 287–300.
20.
MukhiSBrownDD. Transdifferentiation of tadpole pancreatic acinar cells to duct cells mediated by Notch and stromelysin-3. Dev Biol2011; 351: 311–7.
21.
FrancoPGSilvestroffLSotoEFPasquiniJM. Thyroid hormones promote differentiation of oligodendrocyte progenitor cells and improve remyelination after cuprizone-induced demyelination. Exp Neurol2008; 212: 458–67.
HarsanLASteibelJZarembaAAginASapinRPouletPGuignardBParizelNGruckerDBoehmNMillerRHGhandourMS. Recovery from chronic demyelination by thyroid hormone therapy: myelinogenesis induction and assessment by diffusion tensor magnetic resonance imaging. J Neurosci2008; 28: 14189–201.
24.
SilvestroffLBartucciSPasquiniJFrancoP. Cuprizone-induced demyelination in the rat cerebral cortex and thyroid hormone effects on cortical remyelination. Exp Neurol2012; 235: 357–67.
25.
TaylorLCGilmoreWTingJP-YMatsushimaGK. Cuprizone induces similar demyelination in male and female C57BL/6 mice and results in disruption of the estrous cycle. J Neurosci Res2010; 88: 391–402.
26.
JeonHAiJSabriMTariqAShangXChenGMacdonaldRL. Neurological and neurobehavioral assessment of experimental subarachnoid hemorrhage. BMC Neurosci2009; 10: 103–103.
27.
Franco-PonsNTorrenteMColominaMTVilellaE. Behavioral deficits in the cuprizone-induced murine model of demyelination/remyelination. Toxicol Lett2007; 169: 205–13.
28.
KuhlmannTMironVCuiQWegnerCAntelJBruckW. Differentiation block of oligodendroglial progenitor cells as a cause for remyelination failure in chronic multiple sclerosis. Brain2008; 131: 1749–58.
29.
TrakaMArasiKAvilaRLPodojilJRChristakosAMillerSDSolivenPopkoB. A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain2010; 133: 3017–29.
30.
RomeroADiosSBremontMFiguerasANovoaB. Interaction of the attenuated recombinant rIHNV-Gvhsv GFP virus with macrophages from rainbow trout (Oncorhynchus mykiss). Vet Immunol Immunopathol2011; 140: 119–29.
31.
WeinshenkerBG. The natural history of multiple sclerosis: update 1998. Semin Neurol1998; 18: 301–7.
32.
WeinshenkerBGBassBRiceGPNoseworthyJCarriereWBaskervilleJEbersGC. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain1989; 112: 133–46.
33.
DegenhardtARamagopalanSVScalfariAEbersGC. Clinical prognostic factors in multiple sclerosis: a natural history review. Nat Rev Neurol2009; 5: 672–82.
34.
TremlettHZhaoYDevonshireV. Natural history comparisons of primary and secondary progressive multiple sclerosis reveals differences and similarities. J Neurol2009; 256: 374–81.
35.
PrineasJWConnellF. Remyelination in multiple sclerosis. Ann Neurol1979; 5: 22–31.
36.
ReynoldsRCenci di BelloIDawsonMLevineJ. The response of adult oligodendrocyte progenitors to demyelination in EAE. Prog Brain Res2001; 132: 165–74.
37.
BackSATuohyTMChenHWallingfordNCraigAStruveJLuoNLBanineFLiuY. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med2005; 11: 966–72.
38.
FranklinRJFfrench-ConstantC. Remyelination in the CNS: from biology to therapy. Nat Rev Neurosci2008; 9: 839–55.
39.
PaganiERoccaMAGalloARovarisMMartinelliVComiGFilippiM. Regional brain atrophy evolves differently in patients with multiple sclerosis according to clinical phenotype. Am J Neuroradiol2005; 26: 341–6.
40.
TrappBDNaveKA. Multiple sclerosis: an immune or neurodegenerative disorder?Annu Rev Neurosci2008; 31: 247–69.
41.
Weinstock-GuttmanBBhasiKBadgettDTamano-BlancoMMinhasMFeichterJPatrickKMunschauerFBakshiRRamanathanM. Genomic effects of once-weekly, intramuscular interferon-beta1a treatment after the first dose and on chronic dosing: relationships to 5-year clinical outcomes in multiple sclerosis patients. J Neuroimmunol2008; 205: 113–25.
42.
KarussisDTeitelbaumDSicsicCBrennerT. Long-term treatment of multiple sclerosis with glatiramer acetate: natural history of the subtypes of anti-glatiramer acetate antibodies and their correlation with clinical efficacy. J Neuroimmunol2010; 220: 125–30.
43.
ButtinelliCClemenziABorrielloGDenaroFPozzilliCFieschiC. Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. Eur J Neurol2007; 14: 1281–7.
44.
TrojanoMRussoPFuianiAPaolicelliDDi MonteEGranieriERosatiGSavettieriGComiGLivreaP. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFNbeta exposure in multiple sclerosis. Mult Scler2006; 12: 578–85.
45.
Van der WaltAButzkuevenHKolbeSMarriottMAlexandrouEGresleMEganGKilpatrickT. Neuroprotection in multiple sclerosis: a therapeutic challenge for the next decade. Pharmacol Ther2010; 126: 82–93.
Rodriguez-PenaAIbarrolaNIniguezMAMunozABernalJ. Neonatal hypothyroidism affects the timely expression of myelin-associated glycoprotein in the rat brain. J Clin Invest1993; 91: 812–8.
48.
DussaultJHRuelJ. Thyroid hormones and brain development. Annu Rev Physiol1987; 49: 321–34.
49.
IbarrolaNMayer-ProschelMRodriguez-PenaANobleM. Evidence for the existence of at least two timing mechanisms that contribute to oligodendrocyte generation in vitro. Dev Biol1996; 180: 1–21.
50.
AhlgrenSCWallaceHBishopJNeophytouCRaffMC. Effects of thyroid hormone on embryonic oligodendrocyte precursor cell development in vivo and in vitro. Mol Cell Neurosci1997; 9: 420–32.
51.
BillonNJolicoeurCTokumotoYVennstromBRaffM. Normal timing of oligodendrocyte development depends on thyroid hormone receptor alpha 1 (TR alpha 1). EMBO J2002; 21: 6452–60.
52.
CarreJLDemerensCRodriguez-PenaAFlochHHVincendonGSarlieveLL. Thyroid hormone receptor isoforms are sequentially expressed in oligodendrocyte lineage cells during rat cerebral development. J Neurosci Res1998; 54: 584–94.
53.
GaoFBApperlyJRaffM. Cell-intrinsic timers and thyroid hormone regulate the probability of cell-cycle withdrawal and differentiation of oligodendrocyte precursor cells. Dev Biol1998; 197: 54–66.
54.
BaxiEGSchottJTFairchildANKirbyLAKaraniRUapinyoyingPPardo-VillamizarCRothsteinJRBerglesDECalabresiPA. A selective thyroid hormone beta receptor agonist enhances human and rodent oligodendrocyte differentiation. Glia2014; 62: 1513–29.
55.
FuALZhouCYChenX. Thyroid hormone prevents cognitive deficit in a mouse model of Alzheimer’s disease. Neuropharmacology2010; 58: 722–9.
56.
SawanoENegishiTAokiTMurakamiMTashiroT. Alterations in local thyroid hormone signaling in the hippocampus of the SAMP8 mouse at younger ages: association with delayed myelination and behavioral abnormalities. J Neurosci Res2013; 91: 382–92.
57.
NoseworthyJHLucchinettiCRodriguezMWeinshenkerBG. Multiple sclerosis. N Engl J Med2000; 343: 938–52.
58.
FancySPKotterMRHarringtonEPHuangJKZhaoCRowitchDHFranklinRJ. Overcoming remyelination failure in multiple sclerosis and other myelin disorders. Exp Neurol2010; 225: 18–23.
59.
CalzaLFernandezMGiulianiAAloeLGiardinoL. Thyroid hormone activates oligodendrocyte precursors and increases a myelin-forming protein and NGF content in the spinal cord during experimental allergic encephalomyelitis. Proc Natl Acad Sci USA2002; 99: 3258–63.
60.
CalzaLFernandezMGiulianiAD’IntinoGPirondiSSiviliaSParadisiMDesordiNGiardinoL. Thyroid hormone and remyelination in adult central nervous system: a lesson from an inflammatory-demyelinating disease. Brain Res Brain Res Rev2005; 48: 339–46.
AlthausHH. Remyelination in multiple sclerosis: a new role for neurotrophins?Prog Brain Res2004; 146: 415–32.
64.
Dell’acquaMLorenziniLD’IntinoGSiviliaSPasqualettiPPanettaVParadisiMFilippiMBaigueraCPizziMGiardinoLRossiniPMCalzàL. Functional and molecular evidence of myelin- and neuro-protection by thyroid hormone administration in experimental allergic encephalomyelitis. Neuropathol Appl Neurobiol2012; 38: 454–70.
65.
LiningtonCEngelhardtBKapocsGLassmanH. Induction of persistently demyelinated lesions in the rat following the repeated adoptive transfer of encephalitogenic T cells and demyelinating antibody. J Neuroimmunol1992; 40: 219–24.
66.
KornekBStorchMKWeissertRWallstroemEStefferlAOlssonTLiningtonCSchmidbauerMLassmannH. Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol2000; 157: 267–76.
67.
PatrikiosPStadelmannCKutzelniggARauschkaHSchmidbauerMLaursenHSorensenPSBruckWLucchinettiCLassmannH. Remyelination is extensive in a subset of multiple sclerosis patients. Brain2006; 129: 3165–72.
68.
VoseLRVinukondaGJoSMiryODiamondDKorumilliRArshadAZiaMTHuFKaytonRJGammaEFBallabhP. Treatment with thyroxine restores myelination and clinical recovery after intraventricular hemorrhage. J Neurosci2013; 33: 17232–46.
